SynthesisMediators of inflammation2021
Systemic Inflammatory Markers for Predicting Overall Survival in Patients with Osteosarcoma: A Systematic Review and Meta-Analysis.
Synthesis in Mediators of inflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Prognostic value of the immune-inflammatory indices in osteosarcoma: a systematic review and meta-analysis.World journal of surgical oncology · 2026Pooled it
- Development and validation of a biopsy-based model using tumor-associated neutrophils to predict neoadjuvant chemotherapy response in osteosarcoma: a large single-center retrospective cohort study.Journal of bone oncology · 2026Article
- Review
- High Levels of Systemic Inflammatory Markers Associated with Metastasis Incidence in Osteosarcoma.Revista brasileira de ortopedia · 2025Article
- [High Levels of Systemic Inflammatory Markers Associated with Metastasis Incidence in Osteosarcoma].Revista brasileira de ortopedia · 2025Article
- Prognostic significance of T cells and NK cells in osteosarcoma: a dual-center retrospective study.World journal of surgical oncology · 2025Article
- Clinical and Pathological Profile of Children and Adolescents with Osteosarcoma.Diagnostics (Basel, Switzerland) · 2025Article
- Antisense mediated blockade of Dickkopf 1 attenuates tumor survival, metastases and bone damage in experimental osteosarcoma.Scientific reports · 2025Article
- The prognostic significance of lung immune prognostic index in patients with osteosarcoma after chemotherapy.Frontiers in oncology · 2025Article
- Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data.Cancers · 2024Article
- The role of neutrophils in osteosarcoma: insights from laboratory to clinic.Frontiers in immunology · 2024Review
- The role of preoperative hematological inflammatory markers as a predictor of meningioma grade: A systematic review and meta-analysis.Surgical neurology international · 2024Review
- Gossypetin Is a Novel Modulator of Inflammatory Cytokine Production and a Suppressor of Osteosarcoma Cell Growth.Antioxidants (Basel, Switzerland) · 2023Article
- The Prognostic Value of Serum Biomarkers for Survival of Children with Osteosarcoma of the Extremities.Current oncology (Toronto, Ont.) · 2023Article
- Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort.Journal of cancer research and clinical oncology · 2023Article
- Prognostic Impact of Serum CRP Level in Head and Neck Squamous Cell Carcinoma.Frontiers in oncology · 2022Article
- Prognostic significance of modified lung immune prognostic index in osteosarcoma patients.Frontiers in genetics · 2022Article
- Prognostic value of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in laryngeal cancer: What should we expect from a meta-analysis?Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory markers are associated with tumor genesis and progression, but their prognostic significance in osteosarcoma remains unclear. Therefore, we discussed the prognostic value of related inflammatory markers in osteosarcoma through a meta-analysis and systematic review. These inflammatory markers include C-reactive protein (CRP), neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR), and Glasgow prognostic score (GPS).
methodsThe Chinese National Knowledge Infrastructure (CNKI), Wanfang, Chinese Scientific Journals (VIP), PubMed, Embase, and Cochrane libraries were searched. The design of meta-analysis was made based on the PICOS (population, intervention/exposure, control, outcomes, and study design) principles, and STATA 15.1 was used to analyze the data. The Newcastle-Ottawa scale (NOS) was used to assess the quality of included studies. Hazard ratios (HRs) for overall survival (OS) and disease-specific survival (DPS) were extracted for the investigation of the prognostic value of inflammatory markers.
resultsTwelve researches with 2162 osteosarcoma patients were included in total. The pooled results showed that elevated NLR, CRP, and GPS are all greatly related to shortening of OS among patients with osteosarcoma (HR = 1.68,
conclusionWorsened prognosis may be related to high levels of NLR, CRP, and GPS before treatment rather than LMR or PLR, which can provide the basis for clinicians to judge the outcomes of prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.